Incannex Receives HREC Approval For Phase 2 Clinical Trial Assessing IHL-675A For Use In Treatment Of Pain And Function In Rheumatoid Arthritis
Portfolio Pulse from Happy Mohamed
Incannex Healthcare Limited (NASDAQ:IXHL) has received approval from the Human Research Ethics Committee (HREC) for a Phase 2 clinical trial of its proprietary anti-inflammatory drug, IHL-675A, for use in treating rheumatoid arthritis. The trial will be managed by Avance Clinical and will recruit 128 patients across Australia and New Zealand. The results of the trial will contribute to a new drug application dossier with the FDA.
July 13, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Incannex's approval for a Phase 2 clinical trial of IHL-675A could potentially boost the company's stock as it indicates progress in the company's drug development pipeline.
The approval for the Phase 2 clinical trial of IHL-675A is a positive development for Incannex. It indicates that the company is making progress in its drug development pipeline, which could potentially lead to future revenue growth if the drug is successfully commercialized. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100